|Exclusive license agreement with Colorado State University Research Foundation (CSURF) and NeoTREX™ |
|12.18.2008 | Thursday|
IRVINE, CA - Veterinary Diagnostics Institute™ (VDI) today entered into an exclusive license agreement with Colorado State University Research Foundation (CSURF) and NeoTREX™ of Fort Collins, CO for development of a biomarker assay for detection of canine hemangiosarcoma.
The technology, co-invented by faculty at CSU's Animal Cancer Center (a member of CSU's Cancer Supercluster) and investigators at VDI, will be used to detect levels of the enzyme thymidine kinase in dogs using a simple blood test. Hemangiosarcoma occurs most often in large breed dogs over 8 years of age, often resulting in internal hemorrhage leading to death. Other than ultrasound, there are no other prognostic methods to detect hemangiosarcoma in dogs. It is anticipated that this method will be adopted by veterinary clinicians as an early detector of hemangiosarcoma.
There are currently over 75 million pet dogs in the United States. Nearly half of all dogs over the age of ten die from cancer. VDI plans to develop the technology and co-market with another technology to detect lymphoma in dogs.
Veterinary Diagnostics Institute™ (VDI) is a veterinary clinical ventures company dedicated to the research, development and introduction of innovative biomarkers for companion animals.
NeoTREX™ is the enterprise arm of the Cancer Supercluster at CSU. The goal of NeoTREX is to translate research discoveries into products that aid in the prevention, diagnosis and treatment of cancer. NeoTREX is a division of CSU Ventures, Inc., a 501(c)(3) nonprofit corporation.The Cancer Supercluster is a multi-disciplinary group of faculty members at Colorado State University from across campus. The goal is to bring together experts in different areas to work on cancer research.
| Colorado State University |
Director, Business Development
Director of Marketing